Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | HTR6 | P50406 | 11/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29721737 | 0.85 | L3MBTL1 (0.62) | CYP2C19PKMHTR6KMT2AHTT | |
| SCHEMBL14735293 | 0.85 | L3MBTL1 (0.62) | CYP2C19PKMHTR6KMT2AHTT | |
| SCHEMBL23620190 | 0.81 | CYP2C19 (0.61) | CYP2C19PKMHTR6MEN1KMT2A | |
| SCHEMBL2007654 | 0.81 | CYP2C19 (0.61) | CYP2C19PKMHTR6MEN1KMT2A | |
| SCHEMBL18370167 | 0.81 | CYP2C19 (0.61) | CYP2C19PKMHTR6MEN1KMT2A | |
| SCHEMBL2009025 | 0.81 | CYP2C19 (0.61) | CYP2C19PKMHTR6MEN1KMT2A | |
| SCHEMBL30411274 | 0.81 | CYP2C19 (0.61) | CYP2C19PKMHTR6MEN1KMT2A | |
| SCHEMBL30955697 | 0.79 | CYP2C19 (0.58) | CYP2C19PKMHTR6MEN1KMT2A | |
| SCHEMBL24223535 | 0.79 | CYP2C19 (0.55) | CYP2C19PKMHTR6MEN1KMT2A | |
| SCHEMBL23971058 | 0.79 | CYP2C19 (0.58) | CYP2C19PKMHTR6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358875-B2 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis | UCB PHARMA GMBH (DE) | 2025-07-15 | — | — | US | disclosed |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | GILEAD SCIENCES, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| CN-112469710-B | Pyridyl and pyrazinyl- (aza) indole sulfonamides | 优时比制药有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | UCB PHARMA GMBH (DE) | 2024-03-26 | — | — | US | disclosed |
| EP-4074703-B1 | PYRIDINYL-(AZA)INDOLSULFONAMIDES | UCB PHARMA GMBH (DE) | 2023-11-29 | — | — | EP | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| CN-101133056-B | Antitumor compounds | NAT HEALTH RESEARCH INSTITUTES | 2010-12-01 | — | — | CN | disclosed |
| CN-101484454-A | Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition | SOLVAY PHARM B V (NL) | 2009-07-15 | — | — | CN | disclosed |
| EP-2041131-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-7456289-B2 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-11-25 | — | — | US | disclosed |
| CN-101133056-A | Antitumor compounds | NAT HEALTH RESEARCH INSTITUTES (CN) | 2008-02-27 | — | — | CN | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| WO-2008003736-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-10 | — | — | WO | disclosed |
| EP-1838711-A2 | ANTI-TUMOR COMPOUNDS | National Health Research Institutes (TW) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006074041-A2 | ANTI-TUMOR COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-13 | — | — | WO | disclosed |
| US-20060148801-A1 | Anti-tumor compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | CYP2C19 1298/4885PKM 4804/4885HTR6 638/4885 |
| US-12358875-B2 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis | GPR27, GPR18, GPR17 | CYP2C19 2740/4885PKM 3496/4885HTR6 279/4885 |
| US-20060148801-A1 | Anti-tumor compounds | TUBB1, TUBB3, TUBB | CYP2C19 4854/4885PKM 2604/4885HTR6 4219/4885 |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | CYP2C19 662/4885PKM 3090/4885HTR6 70/4885 |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | CYP2C19 1298/4885PKM 4804/4885HTR6 638/4885 |
| US-11939319-B2 | Pyridinyl and pyrazinyl-(asa)indolsulfonamides | GPR17, GPR18, GPR119 | CYP2C19 627/4885PKM 2696/4885HTR6 66/4885 |
| US-12240862-B2 | Inhibitors of peptidylarginine deiminases | PADI4, PADI2, PADI1 | CYP2C19 4410/4885PKM 1135/4885HTR6 3644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.